SENATE RESOLUTION NO. 528
         WHEREAS, Cystic fibrosis, commonly referred to as CF, is a
  genetic disease that affects approximately 30,000 children and
  adults in the United States and nearly 70,000 children and adults
  worldwide, more than 2,000 of whom live in this state; and
 
         WHEREAS, In persons with cystic fibrosis, a defective gene
  causes the body to produce an abnormally thick, sticky mucus that
  clogs the lungs, and these secretions produce life-threatening
  lung infections; the secretions also obstruct the pancreas and
  prevent its digestive enzymes from reaching the intestines to
  help the body break down and absorb food; and
 
         WHEREAS, More than 10 million Americans are symptomless
  carriers of the defective CF gene, and this disease occurs in
  approximately one of every 3,500 live births in the United
  States; and
 
         WHEREAS, The median predicted age of survival for a person
  with cystic fibrosis born in 2017 was 46.2 years; and
 
         WHEREAS, With advances in the treatment of CF, the number
  of adults living with this disease has steadily grown, and
  approximately 900 new cases of cystic fibrosis are diagnosed each
  year; and
 
         WHEREAS, More than 50 percent of the affected population is
  18 years of age or older, and people with the disease have a
  variety of symptoms attributed to the more than 1,800 mutations
  of the CF gene; and
 
         WHEREAS, Infant blood screening to detect genetic defects
  is the most reliable and least costly method to identify persons
  likely to have cystic fibrosis; and
 
         WHEREAS, Early diagnosis of the disease permits early
  treatment, which enhances the quality of life and longevity of
  patients; the treatment of CF depends on the stage of the disease
  and the organs involved; and
 
         WHEREAS, Clearing mucus from the lungs is an important part
  of the daily CF treatment regimen; other types of treatments
  include taking pancreatic enzymes and inhaled antibiotics; and
 
         WHEREAS, A critical component of treating patients with
  cystic fibrosis is access to innovative treatments, which can
  play a crucial role in the lives of patients with CF; and
 
         WHEREAS, There are 11 world-class treatment centers in
  this state which specialize in the diagnosis of cystic fibrosis
  and the care of persons with CF; and
 
         WHEREAS, Improving the length and quality of life for
  people with CF starts with awareness; now, therefore, be it
 
         RESOLVED, That the Senate of the State of Texas, 86th
  Legislature, hereby designate the month of May 2019 as Cystic
  Fibrosis Awareness Month in Texas.
 
  Kolkhorst
   
   
   
    ________________________________ 
        President of the Senate
     
        I hereby certify that the
    above Resolution was adopted by
    the Senate on April 1, 2019.
   
   
   
    ________________________________ 
        Secretary of the Senate
   
   
   
    ________________________________ 
         Member, Texas Senate